A multicenter, international, open-label, safety study of NDO612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND)

September 24, 2018
https://clinicaltrials.gov/ct2/show/NCT02726386
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD

Parkinson's

 

Accepting Participants
(248)661-6540